Stockreport

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF – 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding– Expertise in advan [Read more]